AstraZeneca and Daiichi Sankyo announced promising results from a late-stage clinical trial of their precision drug, Datroway, which significantly improved overall survival in patients with advanced breast cancer. 

The trial compared early treatment with Datroway against chemotherapy, and the drug not only boosted overall survival but also significantly extended progression-free survival, meeting the dual main goals of the study.

Datroway, an antibody-drug conjugate often referred to as a "guided missile" therapy, selectively targets cancer cells by binding to the TROP2 protein found on their surface, minimizing damage to healthy cells, unlike conventional chemotherapy. The drug has already been approved for the treatment of certain forms of breast and lung cancers.

Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, described the trial results as a potential inflection point in treating patients with the poorest prognosis of any type of breast cancer, who urgently need better options.

AstraZeneca further stated that detailed trial results would be shared with regulatory authorities and presented at an upcoming, unspecified medical conference. F

This development marks a critical step forward in precision oncology for patients with hard-to-treat breast cancer variants.